杂志信息/Information
- 刊名:癌症进展
- Oncology Progress Journal
- 主管:国家卫生健康委员会
- 主办:中国医学科学院
- 社长:张凌
- 主编:赵平
- 编辑部主任:穆红
- 编辑部副主任:陈闻
- 编辑出版:中国协和医科大学出版社
《癌症进展》编辑部
100730,北京东单三条9号
电话:010-57528107
E-mail:azjzzz@163.com
http://www.aizhengjinzhan.com - 市场运营:惠生文化传媒(北京)有限公司
李长松 沈杰 - 印刷:北京联合互通彩色印刷有限公司
- 国内统一连续出版物号:CN 11-4971/R
- 国际标准连续出版物号ISSN 1672-1535
下载专区/Download
订阅电子期刊/Subscribe
提交您的邮箱地址,我们会定期将电子期刊 发送到您的邮箱
期刊检索/Journal Search
扫一扫,关注
2016 年第 5 期 第 14 卷
膀胱癌CD34及podoplanin表达情况与淋巴转移及组织浸润间的相关性分析
作者:
单位:
关键词:膀胱癌CD34肾小球足突细胞膜黏蛋白淋巴转移组织浸润
- 摘要:
- 【摘要】目的探讨膀胱癌组织中CD34及肾小球足突细胞膜黏蛋白(podoplanin)的表达情况,并分析CD34及podoplanin表达与淋巴转移及组织浸润的关系。
- Objective To analysis the expression of CD34 and podoplanin in bladder cancer and analysis the correlation correlation between lymphatic metastasis and invasion. Methods: Collect 10 cases of normal bladder tissue as control group, collect the 45 cases of bladder cancer tissues as observation group, compared the CD34 and podoplanin expression between two groups. According to the situation of lymphatic metastasis at the same time, observation group was divided into patients without lymph node metastasis and patients with lymph node metastasis, contrast CD34 and podoplanin expression between the two groups. And according to the invasion of situation, observation group was divided into infiltrating does not exceed not infiltration in the muscular layer group and more than muscle layer infiltration, contrast between the two groups of CD34 and podoplanin expression. Results: CD34 and podoplanin positive expression rate of observation group were significantly higher than the control group(P<0.05); CD34 and podoplanin positive expression rate of transfer group were significantly higher than without metastasis group(P<0.05); CD34 and podoplanin positive expression rate of invasive group were significantly higher than no invasive group(P<0.05). Conclusion: Bladder cancer tissues CD34 and podoplanin positive rate increased significantly, and bladder cancer invasion more than muscle layer and lymph node metastases can increase CD34 and podoplanin same positive rate.